{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Pegylated+Interferon%2Fribavirin", "query": { "intervention": "Pegylated Interferon/ribavirin" }, "page_size": 10 }, "pagination": { "page": 1, "page_size": 10, "total_count": 126, "total_pages": 13, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Pegylated+Interferon%2Fribavirin&page=2&page_size=10", "previous_page_url": null }, "source": "remote", "last_synced_at": "2026-10-02T06:37:16.601Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT00863239", "title": "Phase 2B Dose Ranging Study of Locteron Plus Ribavirin to Treat HCV", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Hepatitis C, Chronic" ], "interventions": [ { "name": "ribavirin", "type": "DRUG" }, { "name": "Locteron™ (controlled-release interferon alpha 2b)", "type": "DRUG" }, { "name": "PEG-Intron™", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Biolex Therapeutics, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "69 Years", "sex": "ALL", "summary": "18 Years to 69 Years" }, "enrollment_count": 116, "start_date": "2009-03", "completion_date": "2011-11", "has_results": false, "last_update_posted_date": "2012-02-02", "last_synced_at": "2026-10-02T06:37:16.601Z", "location_count": 13, "location_summary": "Chula Vista, California • Oceanside, California • San Diego, California + 10 more", "locations": [ { "city": "Chula Vista", "state": "California" }, { "city": "Oceanside", "state": "California" }, { "city": "San Diego", "state": "California" }, { "city": "Louisville", "state": "Kentucky" }, { "city": "Laurel", "state": "Maryland" } ], "official_url": "https://clinicaltrials.gov/study/NCT00863239" }, { "nct_id": "NCT01185028", "title": "A Safety and Tolerability Study of Nitazoxanide in HIV-HCV Treatment Failures", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Hepatitis C Infection", "HIV Infection" ], "interventions": [ { "name": "Nitazoxanide With Pegylated Interferon And Ribavirin", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "National Institutes of Health Clinical Center (CC)", "sponsor_class": "NIH", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "99 Years", "sex": "ALL", "summary": "18 Years to 99 Years" }, "enrollment_count": 8, "start_date": "2010-08", "completion_date": "2011-10", "has_results": true, "last_update_posted_date": "2021-10-05", "last_synced_at": "2026-10-02T06:37:16.601Z", "location_count": 4, "location_summary": "Washington D.C., District of Columbia • Bethesda, Maryland", "locations": [ { "city": "Washington D.C.", "state": "District of Columbia" }, { "city": "Washington D.C.", "state": "District of Columbia" }, { "city": "Washington D.C.", "state": "District of Columbia" }, { "city": "Bethesda", "state": "Maryland" } ], "official_url": "https://clinicaltrials.gov/study/NCT01185028" }, { "nct_id": "NCT01309932", "title": "Safety Study of Pegylated Interferon Lambda Plus Single or 2 Direct Antiviral Agents With Ribavirin", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Hepatitis C" ], "interventions": [ { "name": "Pegylated Interferon Lambda (pegIFNλ)", "type": "BIOLOGICAL" }, { "name": "BMS-790052 (NS5A Inhibitor)", "type": "DRUG" }, { "name": "Ribavirin (RBV)", "type": "DRUG" }, { "name": "BMS-650032 (NS3 Protease Inhibitor)", "type": "DRUG" }, { "name": "Pegylated Interferon Alfa-2a (pegIFNα-2a)", "type": "BIOLOGICAL" }, { "name": "Placebo (PBO) for BMS-650032 (Placebo for NS3 Protease Inhibitor)", "type": "DRUG" }, { "name": "Placebo (PBO) for BMS-790052 (Placebo for NS5A Inhibitor)", "type": "DRUG" }, { "name": "Placebo for Ribavirin (RBV)", "type": "DRUG" } ], "intervention_types": [ "BIOLOGICAL", "DRUG" ], "sponsor": "Bristol-Myers Squibb", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "70 Years", "sex": "ALL", "summary": "18 Years to 70 Years" }, "enrollment_count": 165, "start_date": "2011-03", "completion_date": "2014-09", "has_results": false, "last_update_posted_date": "2015-10-09", "last_synced_at": "2026-10-02T06:37:16.601Z", "location_count": 13, "location_summary": "Phoenix, Arizona • Palm Springs, California • Aurora, Colorado + 10 more", "locations": [ { "city": "Phoenix", "state": "Arizona" }, { "city": "Palm Springs", "state": "California" }, { "city": "Aurora", "state": "Colorado" }, { "city": "New Haven", "state": "Connecticut" }, { "city": "Lutherville", "state": "Maryland" } ], "official_url": "https://clinicaltrials.gov/study/NCT01309932" }, { "nct_id": "NCT01153919", "title": "Romiplostim in Treating Hepatitis C-Infected Patients With Thrombocytopenia", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Hepatitis C Infection", "Thrombocytopenia" ], "interventions": [ { "name": "romiplostim", "type": "BIOLOGICAL" }, { "name": "ribavirin", "type": "DRUG" }, { "name": "placebo", "type": "OTHER" }, { "name": "PEG-interferon alfa-2a", "type": "BIOLOGICAL" }, { "name": "laboratory biomarker analysis", "type": "OTHER" } ], "intervention_types": [ "BIOLOGICAL", "DRUG", "OTHER" ], "sponsor": "University of Southern California", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 27, "start_date": "2010-06-30", "completion_date": "2018-07-14", "has_results": false, "last_update_posted_date": "2017-04-11", "last_synced_at": "2026-10-02T06:37:16.601Z", "location_count": 1, "location_summary": "Los Angeles, California", "locations": [ { "city": "Los Angeles", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT01153919" }, { "nct_id": "NCT00487318", "title": "Fluvastatin, Rosuvastatin Added to Pegylated Interferon and Ribavirin", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Chronic Hepatitis C" ], "interventions": [ { "name": "standard of care", "type": "DRUG" }, { "name": "fluvastatin", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Bader, Ted, M.D.", "sponsor_class": "INDIV", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "70 Years", "sex": "ALL", "summary": "18 Years to 70 Years" }, "enrollment_count": 40, "start_date": "2007-06", "completion_date": "2010-10", "has_results": false, "last_update_posted_date": "2012-08-21", "last_synced_at": "2026-10-02T06:37:16.601Z", "location_count": 1, "location_summary": "Oklahoma City, Oklahoma", "locations": [ { "city": "Oklahoma City", "state": "Oklahoma" } ], "official_url": "https://clinicaltrials.gov/study/NCT00487318" }, { "nct_id": "NCT01306617", "title": "A Study to Evaluate the Efficacy, Safety, and Pharmacokinetics of ABT-450 With Ritonavir (ABT-450/r) When Given Together With ABT-333 and Ribavirin (RBV) in Treatment-Naïve and Non-responder Subjects With Genotype 1 Chronic Hepatitis C Virus (HCV) Infection", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Chronic Hepatitis C Infection", "Hepatitis C", "Hepatitis C Virus" ], "interventions": [ { "name": "ABT-450", "type": "DRUG" }, { "name": "ABT-333", "type": "DRUG" }, { "name": "ribavirin", "type": "DRUG" }, { "name": "ritonavir", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "AbbVie (prior sponsor, Abbott)", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "65 Years", "sex": "ALL", "summary": "18 Years to 65 Years" }, "enrollment_count": 50, "start_date": "2011-02", "completion_date": "2012-10", "has_results": true, "last_update_posted_date": "2015-01-08", "last_synced_at": "2026-10-02T06:37:16.601Z", "location_count": 11, "location_summary": "Los Angeles, California • Aurora, Colorado • Gainesville, Florida + 8 more", "locations": [ { "city": "Los Angeles", "state": "California" }, { "city": "Aurora", "state": "Colorado" }, { "city": "Gainesville", "state": "Florida" }, { "city": "Springfield", "state": "Massachusetts" }, { "city": "Kansas City", "state": "Missouri" } ], "official_url": "https://clinicaltrials.gov/study/NCT01306617" }, { "nct_id": "NCT00148031", "title": "Improving Hepatitis C Treatment in Injection Drug Users", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE4" ], "conditions": [ "Hepatitis C", "Liver Diseases", "Drug Abuse", "Alcoholism" ], "interventions": [ { "name": "Pegylated Interferon and Ribavirin", "type": "DRUG" }, { "name": "Psychosocial", "type": "BEHAVIORAL" }, { "name": "On-site (MMT Clinic) HCV evaluation and treatment", "type": "BEHAVIORAL" }, { "name": "Off-site HCV evaluation and treatment", "type": "BEHAVIORAL" } ], "intervention_types": [ "DRUG", "BEHAVIORAL" ], "sponsor": "State University of New York - Upstate Medical University", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "65 Years", "sex": "ALL", "summary": "18 Years to 65 Years" }, "enrollment_count": 111, "start_date": "2003-09", "completion_date": "2007-03", "has_results": false, "last_update_posted_date": "2013-04-24", "last_synced_at": "2026-10-02T06:37:16.601Z", "location_count": 2, "location_summary": "Syracuse, New York", "locations": [ { "city": "Syracuse", "state": "New York" }, { "city": "Syracuse", "state": "New York" } ], "official_url": "https://clinicaltrials.gov/study/NCT00148031" }, { "nct_id": "NCT02966795", "title": "A Study of of Glecaprevir/Pibrentasvir in Adults With Chronic Hepatitis C Virus (HCV) Genotype 5 or 6 Infection", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Hepatitis C Virus (HCV)" ], "interventions": [ { "name": "Glecaprevir/Pibrentasvir", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "AbbVie", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 84, "start_date": "2017-01-25", "completion_date": "2018-08-29", "has_results": true, "last_update_posted_date": "2021-07-30", "last_synced_at": "2026-10-02T06:37:16.601Z", "location_count": 6, "location_summary": "San Diego, California • San Francisco, California • West Hollywood, California + 2 more", "locations": [ { "city": "San Diego", "state": "California" }, { "city": "San Diego", "state": "California" }, { "city": "San Francisco", "state": "California" }, { "city": "West Hollywood", "state": "California" }, { "city": "Philadelphia", "state": "Pennsylvania" } ], "official_url": "https://clinicaltrials.gov/study/NCT02966795" }, { "nct_id": "NCT00882908", "title": "A Study of TMC435 in Combination With Pegylated Interferon Alp\\Fa-2a and Ribavirin in Patients Infected With Genotype 1 Hepatitis C Virus Who Never Received Treatment", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Hepatitis C" ], "interventions": [ { "name": "TMC435", "type": "DRUG" }, { "name": "Ribavirin (R)", "type": "DRUG" }, { "name": "PegIFNα-2a (P)", "type": "DRUG" }, { "name": "Placebo", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Tibotec Pharmaceuticals, Ireland", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "70 Years", "sex": "ALL", "summary": "18 Years to 70 Years" }, "enrollment_count": 386, "start_date": "2009-06", "completion_date": "2011-04", "has_results": true, "last_update_posted_date": "2014-06-16", "last_synced_at": "2026-10-02T06:37:16.601Z", "location_count": 12, "location_summary": "Los Angeles, California • Jacksonville, Florida • Orlando, Florida + 9 more", "locations": [ { "city": "Los Angeles", "state": "California" }, { "city": "Jacksonville", "state": "Florida" }, { "city": "Orlando", "state": "Florida" }, { "city": "Palm Harbor", "state": "Florida" }, { "city": "Chicago", "state": "Illinois" } ], "official_url": "https://clinicaltrials.gov/study/NCT00882908" }, { "nct_id": "NCT00239733", "title": "Anti-D for Treating Thrombocytopenia in Adults Infected With Hepatitis C Virus With or Without HIV Co-Infection", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE4" ], "conditions": [ "Thrombocytopenia", "Hepatitis C", "HIV Infections" ], "interventions": [ { "name": "Anti-D", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "National Institute of Allergy and Infectious Diseases (NIAID)", "sponsor_class": "NIH", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 6, "start_date": "2005-03", "completion_date": "2010-02", "has_results": true, "last_update_posted_date": "2017-05-16", "last_synced_at": "2026-10-02T06:37:16.601Z", "location_count": 1, "location_summary": "New York, New York", "locations": [ { "city": "New York", "state": "New York" } ], "official_url": "https://clinicaltrials.gov/study/NCT00239733" } ] }